CN111527073A - 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法 - Google Patents

一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法 Download PDF

Info

Publication number
CN111527073A
CN111527073A CN201880076729.3A CN201880076729A CN111527073A CN 111527073 A CN111527073 A CN 111527073A CN 201880076729 A CN201880076729 A CN 201880076729A CN 111527073 A CN111527073 A CN 111527073A
Authority
CN
China
Prior art keywords
compound
degrees
minus
plus
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880076729.3A
Other languages
English (en)
Other versions
CN111527073B (zh
Inventor
王建非
张杨
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Kanion Pharmaceutical Co Ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN111527073A publication Critical patent/CN111527073A/zh
Application granted granted Critical
Publication of CN111527073B publication Critical patent/CN111527073B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

本发明公开了一种4‑(萘‑1‑基)‑4H‑1,2,4‑三唑类化合物晶型及其制备方法，还包括所述晶型在制备治疗与尿酸水平异常相关疾病药物中的应用。
Figure DDA0002511188960000011

Description

PCT国内申请，说明书已公开。

Claims (35)

  1. PCT国内申请，权利要求书已公开。
CN201880076729.3A 2017-12-15 2018-12-17 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法 Active CN111527073B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017113522910 2017-12-15
CN201711352291 2017-12-15
CN201711376759X 2017-12-19
CN201711376759 2017-12-19
PCT/CN2018/121477 WO2019114838A1 (zh) 2017-12-15 2018-12-17 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法

Publications (2)

Publication Number Publication Date
CN111527073A true CN111527073A (zh) 2020-08-11
CN111527073B CN111527073B (zh) 2022-03-15

Family

ID=66819954

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880076729.3A Active CN111527073B (zh) 2017-12-15 2018-12-17 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法

Country Status (7)

Country Link
US (1) US11352331B2 (zh)
EP (1) EP3725781B1 (zh)
JP (1) JP7282780B2 (zh)
CN (1) CN111527073B (zh)
DK (1) DK3725781T3 (zh)
ES (1) ES2934533T3 (zh)
WO (1) WO2019114838A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918377A (zh) * 2007-11-27 2010-12-15 亚德生化公司 新颖化合物和组合物以及使用方法
CN105985295A (zh) * 2015-02-17 2016-10-05 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物
CN106220577A (zh) * 2016-07-26 2016-12-14 苏州明锐医药科技有限公司 利新洛德的制备方法
WO2017215589A1 (zh) * 2016-06-17 2017-12-21 南京明德新药研发股份有限公司 一种卤代化合物及其轴手性异构体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022301B1 (ru) * 2010-12-30 2015-12-30 Ардеа Биосайнсиз, Инк. Полиморфные формы 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты и их применение
CA2931430A1 (en) * 2013-11-22 2015-05-28 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad and its sodium salt
CN105294585B (zh) 2014-07-02 2019-02-12 成都海创药业有限公司 一种治疗痛风的化合物
CN105622531A (zh) * 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918377A (zh) * 2007-11-27 2010-12-15 亚德生化公司 新颖化合物和组合物以及使用方法
CN105985295A (zh) * 2015-02-17 2016-10-05 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物
WO2017215589A1 (zh) * 2016-06-17 2017-12-21 南京明德新药研发股份有限公司 一种卤代化合物及其轴手性异构体
CN106220577A (zh) * 2016-07-26 2016-12-14 苏州明锐医药科技有限公司 利新洛德的制备方法

Also Published As

Publication number Publication date
KR20200111173A (ko) 2020-09-28
JP7282780B2 (ja) 2023-05-29
EP3725781A4 (en) 2021-08-04
US11352331B2 (en) 2022-06-07
EP3725781B1 (en) 2022-11-30
ES2934533T3 (es) 2023-02-22
WO2019114838A1 (zh) 2019-06-20
US20210078960A1 (en) 2021-03-18
DK3725781T3 (da) 2022-12-19
CN111527073B (zh) 2022-03-15
EP3725781A1 (en) 2020-10-21
JP2021506826A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
EP3279188B1 (en) Axially chiral isomers, and preparation methods therefor and pharmaceutical uses thereof
CN102702008B (zh) 阿戈美拉汀硫酸复合物及其制备方法
WO2021023194A1 (zh) 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法
EP4286386A1 (en) Salt form and crystal form of pyrazole substituted imidazo[1,2- a]quinoxaline derivative
WO2022171044A1 (zh) 一种氧氮杂螺环化合物、其盐型及其晶型
EP4046686B1 (en) Salt types, crystal forms, and preparation methods for benzopyrazole compounds as rho kinase inhibitors
CN109476611B (zh) 一种卤代化合物及其轴手性异构体
WO2021023195A1 (zh) 吡嗪-2（1h）-酮类化合物的d晶型及其制备方法
CN111527073B (zh) 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法
US20240025920A1 (en) Salt form used as cdc7 inhibitor and crystal form thereof
KR102660247B1 (ko) 4-(나프탈렌-1-일)-4h-1, 2, 4-트리아졸계 화합물의 결정 형태, 염 형태 및 이의 제조방법
CN111386268B (zh) 一种urat1抑制剂的晶型及其制备方法
EP3896063B1 (en) Crystalline forms of the syk inhibitor 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salt (1:1)
EP4332097A1 (en) Crystal form of thiophene derivative and preparation method therefor
WO2019057142A1 (zh) 一种内磺酰胺化合物结晶
CN111683946B (zh) 一种三并环化合物的晶型、盐型及其制备方法
WO2023125947A1 (zh) 四氢异喹啉类化合物的可药用盐、晶型及其用途
WO2023274040A1 (zh) 一种三唑并吡啶取代的吲唑类化合物的晶型及其制备方法
CN117355528A (zh) 吡咯并三嗪类化合物的盐型、其晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034227

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230424

Address after: 222047 Jiangning Industrial Park, Lianyungang Economic and Technological Development Zone, Jiangsu Province

Patentee after: JIANGSU KANION PHARMACEUTICAL Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee before: Nanjing Mingde New Drug Development Co.,Ltd.